Posts by Heather Hare

Ann and David Nelson: I am the DIFFERENCE

I am the DIFFERENCE Early on in their relationship, Ann and David Nelson decided they would prepare as if Dave had...

HD Insights Volume 16 (PDF)

To read a non-PDF version of HD Insights Vol. 16, click here.

2016: Advances and Challenges in HD Therapeutic Development

By: Meredith A. Achey, BM The year 2016 brought a number of notable developments in HD research and therapeutic development....

Brief report: Pfizer Amaryllis trial ends: negative results lead to termination of extension study

By: Molly J. Elson, BA Pfizer’s Phase 2 trial of PF-02545920, a PDE-10 inhibitor, failed to find the efficacy for...

Highly Cited HD Research

In this edition of HD Insights, we take a look at impactful HD research articles of 2015. We searched Thomson...

Research Round-Up

Research Round-Up

By: Lise Munsie, PhD In pharma… The well-tolerated, FDA-approved drug metformin is an antidiabetic drug that mimics caloric restriction. Jin...

MEET THE COMPANY: uniQure

VITAL SIGNS NAME: uniQure STOCK SYMBOL: QURE    SHARE PRICE AS OF 2/17/17: $6.31 52-WEEEK RANGE AS OF 2/17/17: $5.25-$16.40...

MEET THE SCIENTIST: Pavlina Konstantinova, MSc, PhD

MEET THE SCIENTIST: Pavlina Konstantinova, MSc, PhD

VITAL SIGNS NAME: Pavlina Konstantinova, MSc, PhD TITLE: Director of Emerging Technologies and Huntington Disease Program Leader, uniQure EDUCATION: MSc,...

MEET THE COMPOUND: AMT-130

MEET THE COMPOUND: AMT-130

By: Meredith A. Achey, BM MANUFACTURER: uniQure COMPOUND: Artificial micro RNA targeting human huntingtin, carried by an adeno-associated virus 5...

Highlights from the Journal of HD

Assistive technology for cognition in HD By: Marleen R. van Walsem, MSc, Emilie I. Howe, MSc and Jan C. Frich,...

1 2 3 4 12